AP736

AP736 is a potent tyrosinase inhibitor (IC50 = 0.9 μM) with anti-melanogenesis activity in normal human melanocytes (IC50 = 0.11 μM) . AP736 suppresses the expression of tyrosinase and TRP-1/2 by inhibiting the cAMP-PKA-CREB signalling axis, leading to reduced microphthalmia-associated transcription factor (MITF) transcripts and proteins. AP736 can be used for melanogenesis and hyperpigmentation research[1][2].

Product Specifications

CAS Number

[1365531-21-0]

UNSPSC

12352005

Target

PKA; Tyrosinase

Related Pathways

Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Others

Smiles

O=C(C1=C(OC)C=C(OC)C(C23CC4CC(C3)CC(C2)C4)=C1)NCC5=CC=C(C=C5O)O

Molecular Formula

C26H31NO5

Molecular Weight

437.53

References & Citations

[1]Shin HJ, et al. Development and evaluation of topical formulations for a novel skin whitening agent (AP736) using Hansen solubility parameters and PEG-PCL polymers. Int J Pharm. 2018 Dec 1;552 (1-2) :251-257.|[2]Lee CS, et al. A novel adamantyl benzylbenzamide derivative, AP736, suppresses melanogenesis through the inhibition of cAMP-PKA-CREB-activated microphthalmia-associated transcription factor and tyrosinase expression. Exp Dermatol. 2013 Nov;22 (11) :762-4.